Ron, as I said before, this technology has so many potential applications that several of them should see commercial success if management can deliver on their promises. The production cost of many of those actual/ potential products seems to be pretty low. Thus, if any of them can capture the market, they should generate substantial amount of cash flow. R & D team of the company is world class capable of making breakthroughs. They have also been able to attract government attention (obtained funds from the government twice in the last six months) and established partnership with big players in relevant industries (partnerships with Lydall and Corning).
Stemdisc450 is the first of the series of the actual/potential products.
Stemdisc450 product launch: If you read between the lines of the NR dated Otc 22, 2010, you will see that they are supposed start working on testing the stemage software, which is complementary to stemdisc450. Stemdisc450 is not likely to add any value to stem cell research unless you can record the data and make inferences. That's why it is critical to launch them together. I expect to see some NR regarding sales contract or letter of intent or any sorts of agreement with a distributor by the end of this month.
This company has huge potential, but has to deliver to attract investor attention. It is still a concept stock and market does not have any appetite for any concept stock now; they will have to show some real products that are functionable and value-additive. However, they are very close to commercializing their first product. If you take risk at this point of view, the potential for return is very high. That's why I started buying this stock last summer and increased my position when it dropped below 10 cents. I expect something significant before the Christmas.JMHO.
Market Data 
Markets 
AI
